Please assess the completion status of the following clinical trial:

Trial Title: Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Double-blind phases: adults age 18 and above; Open-label extension: Adults and children aged 7 years and older.~* Was diagnosed with Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS) based upon clinical signs and symptoms~* Had documented mutation in NLRP-3 (Cold Induced Autoinflammatory Syndrome-1 or CIAS1) in subject or relative, and willingness to have a confirmatory genetic (Deoxyribonucleic acid or DNA) test (cheek swab).~* Was able to understand and comply with study procedures and was able to provide informed consent~* If female, was not currently pregnant and was willing to use contraception during the study~Exclusion Criteria:~* Had evidence of untreated tuberculosis or other conditions/therapies that made the subject inappropriate for this study.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Some subjects were treated with Placebo in the Study. This occurred (if subject randomized to Placebo) either during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24).
- rilonacept 160 mg (Type: ACTIVE_COMPARATOR): If randomized to rilonacept, subjects received this treatment during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24). All subjects received rilonacept 160 mg during weeks 6-14 (between Parts A and B).~Study drug is administered as a 2.0 mL subcutaneous injection once a week. At baseline (week 0) subjects receive a loading dose of rilonacept 320 mg.
- Open-Label rilonacept 160 mg (Type: OTHER): After week 24 (the end of part B), all subjects went into weekly dosing of open label rilonacept 160 mg. During this phase of the study, adolescents aged 7 and above were entered into the study and rilonacept was dosed as 2.2 mg/kg injections, up to 160 mg, per week.~Study drug is administered as a 2.0 mL subcutaneous injection once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).